Physician profile
Michael J Parker
NPI 1104808898
$54,583.95
in general payments reported to CMS, 2019-2025
24 companies · $6,426 in 2025
The $6,426 reported for 2025 was more than what 89% of Otolaryngic Allergy providers received nationally (typical 2025 total: $449).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,518 · 2020: $8,004 · 2021: $13K · 2022: $8,582 · 2023: $5,295 · 2024: $5,969 · 2025: $6,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $2,678 · Travel and Lodging: $197 · Consulting Fee: $150 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,575.00 |
| Food and Beverage | $2,678.22 |
| Travel and Lodging | $196.63 |
| Consulting Fee | $150.00 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $48,414.90 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,599.18 | 2021-2025 | Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $833.49 | 2022-2025 | Nucala, Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $752.80 | 2019-2025 | |
| Inspire Medical Systems, INC. | $744.91 | 2019-2025 | Inspire |
| Alk-Abello, INC | $206.77 | 2021-2025 | Grastek, Odactra, Ragwitek |
| Avadel Cns Pharmaceuticals, LLC | $196.84 | 2024-2025 | Lumryz |
| Medtronic, INC. | $166.92 | 2024 | Stealthstation S8 Platform, Propel |
| Genzyme Corporation | $104.32 | 2022 | |
| Novartis Pharmaceuticals Corporation | $83.72 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $71.20 | 2021 | |
| Fisher & Paykel Healthcare INC | $69.42 | 2022-2024 | Fisher & Paykel Healthcare |
| Kaleo, INC. | $44.09 | 2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $41.70 | 2025 | Neffy |
| Genentech USA, INC. | $39.28 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Itamar Medical INC | $35.00 | 2025 | Watchpatone |
| Axsome Therapeutics, INC. | $34.52 | 2023 | Sunosi |
| Aerin Medical INC. | $28.94 | 2024 | |
| Intersect Ent, INC. | $22.86 | 2020 | |
| Amgen INC. | $22.68 | 2025 | Tezspire |
| Phadia US INC. | $21.40 | 2021 | |
| Resmed Corp | $17.59 | 2021 | |
| Allergan, INC. | $15.76 | 2020 | |
| Collegium Pharmaceutical, INC. | $15.66 | 2025 | Xtampza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.